LRP5 and breast carcinoma: Furthermore, internally truncated form of LRP5 (LRP5Delta) has recently been reported to be resistant to DKK1 inhibition and thus contributes to the activation of Wnt/β-catenin signaling in parathyroid and breast cancer [40], [41].